UPDATE: Discontinuation of Humulin® 50/50 (50% Human Insulin Isophane Suspension and 50% Human Insulin Injection [rDNA Origin])

Dear Healthcare Professional:

As previously communicated in August 2009, Eli Lilly and Company, after careful consideration, has decided to stop producing Humulin® 50/50. Use of this insulin has been declining and it is estimated that about 3000 patients nationwide will be impacted by this discontinuation.

Our first priority is to assist patients in transitioning as smoothly as possible to an alternate insulin therapy. Lilly is notifying HCPs regarding the timing for the discontinuation to allow affected patients sufficient time to transfer to alternate insulin formulations or treatments.

Based on *current* patient demand and our *current* stock of Humulin 50/50, Lilly anticipates this insulin formulation should be available at pharmacies until December 2009, rather than April 2010, as originally projected. All vials of Humulin 50/50 shipped before that date will now have the following notice printed on the carton: "Humulin® 50/50 is being discontinued. Contact your physician to change to another insulin. For information call 1-800-545-5979."

To assist you in communicating information concerning this product discontinuation to your patients who currently use Humulin 50/50, enclosed are copies of the patient information sheet. The sheet will inform patients about the discontinuation and provide answers to questions they might have. To avoid confusion, please be sure to distribute the sheet only to patients currently using Humulin 50/50.

For additional information, Lilly is available to answer your questions at 1-800-LillyRx (1-800-545-5979) from 9 AM to 5 PM ET, Monday through Friday.

Sincerely,

Sherry A. Martin, MD
Endocrine, US Medical Division
Lilly USA, LLC
Indianapolis, IN

Humulin® 50/50
50% NPH and 50% Regular human insulin (recombinant DNA origin)

HI60759 1109 PRINTED IN USA

Lilly